Mayer LD[au] - Search Results

Year	Number of Results
1949	3
1950	1
1951	3
1952	1
1955	1
1956	1
1958	1
1960	1
1967	1
1972	1
1973	1
1974	2
1981	1
1982	1
1983	1
1984	1
1985	3
1986	4
1987	1
1988	3
1989	3
1990	7
1991	1
1993	5
1994	3
1995	4
1997	5
1998	4
1999	4
2000	8
2001	10
2002	10
2003	8
2004	8
2005	4
2006	4
2007	5
2008	2
2009	3
2010	5
2011	2
2012	2
2013	1
2014	2
2015	1
2016	1
2017	2
2018	2
2019	2
2021	0

1

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.

Mayer LD, Tardi P, Louie AC. Mayer LD, et al. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31213803 Free PMC article. Review.

2

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. Abraham SA, et al. Among authors: mayer ld. Methods Enzymol. 2005;391:71-97. doi: 10.1016/S0076-6879(05)91004-5. Methods Enzymol. 2005. PMID: 15721375

3

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB. Waterhouse DN, et al. Among authors: mayer ld. Drug Saf. 2001;24(12):903-20. doi: 10.2165/00002018-200124120-00004. Drug Saf. 2001. PMID: 11735647 Review.

4

Improving combination cancer therapy: the CombiPlex^® development platform.

Tolcher AW, Mayer LD. Tolcher AW, et al. Among authors: mayer ld. Future Oncol. 2018 Jun;14(13):1317-1332. doi: 10.2217/fon-2017-0607. Epub 2018 Jan 24. Future Oncol. 2018. PMID: 29363994 Free article. Review.

5

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.

Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC. Lin TL, et al. Among authors: mayer ld. Cancer Chemother Pharmacol. 2019 Jul;84(1):163-173. doi: 10.1007/s00280-019-03856-9. Epub 2019 May 16. Cancer Chemother Pharmacol. 2019. PMID: 31098682 Free PMC article. Clinical Trial.

6

Seasonal allergy.

KAUFMANN M, MAYER LD. KAUFMANN M, et al. Among authors: mayer ld. J Ky State Med Assoc. 1956 Feb;54(2):137-44. J Ky State Med Assoc. 1956. PMID: 13295651 No abstract available.

7

Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.

Liboiron BD, Mayer LD. Liboiron BD, et al. Among authors: mayer ld. Ther Deliv. 2014 Feb;5(2):149-71. doi: 10.4155/tde.13.149. Ther Deliv. 2014. PMID: 24483194 Review.

8

Optimizing combination chemotherapy by controlling drug ratios.

Mayer LD, Janoff AS. Mayer LD, et al. Mol Interv. 2007 Aug;7(4):216-23. doi: 10.1124/mi.7.4.8. Mol Interv. 2007. PMID: 17827442 Review.

9

Tumor chemosensitization strategies based on apoptosis manipulations.

Shabbits JA, Hu Y, Mayer LD. Shabbits JA, et al. Among authors: mayer ld. Mol Cancer Ther. 2003 Aug;2(8):805-13. Mol Cancer Ther. 2003. PMID: 12939471 Free article. Review. No abstract available.

10

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Dicko A, Mayer LD, Tardi PG. Dicko A, et al. Among authors: mayer ld. Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41. doi: 10.1517/17425247.2010.538678. Expert Opin Drug Deliv. 2010. PMID: 21118030 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results